These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38807597)

  • 1. Protein kinase CK2α is overexpressed in classical hodgkin lymphoma, regulates key signaling pathways, PD-L1 and may represent a new target for therapy.
    Ruggeri E; Frezzato F; Mouawad N; Pizzi M; Scarmozzino F; Capasso G; Trimarco V; Quotti Tubi L; Cellini A; Cavarretta CA; Ruocco V; Serafin A; Angotzi F; Danesin N; Manni S; Facco M; Piazza F; Trentin L; Visentin A
    Front Immunol; 2024; 15():1393485. PubMed ID: 38807597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth.
    Pizzi M; Piazza F; Agostinelli C; Fuligni F; Benvenuti P; Mandato E; Casellato A; Rugge M; Semenzato G; Pileri SA
    Oncotarget; 2015 Mar; 6(9):6544-52. PubMed ID: 25788269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of CK2β subunit down-regulation on Akt signalling in HK-2 renal cells.
    Alcaraz E; Vilardell J; Borgo C; Sarró E; Plana M; Marin O; Pinna LA; Bayascas JR; Meseguer A; Salvi M; Itarte E; Ruzzene M
    PLoS One; 2020; 15(1):e0227340. PubMed ID: 31910234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma.
    Zheng Y; McFarland BC; Drygin D; Yu H; Bellis SL; Kim H; Bredel M; Benveniste EN
    Clin Cancer Res; 2013 Dec; 19(23):6484-94. PubMed ID: 24036851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.
    Manni S; Brancalion A; Mandato E; Tubi LQ; Colpo A; Pizzi M; Cappellesso R; Zaffino F; Di Maggio SA; Cabrelle A; Marino F; Zambello R; Trentin L; Adami F; Gurrieri C; Semenzato G; Piazza F
    PLoS One; 2013; 8(9):e75280. PubMed ID: 24086494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic CK2 inhibition attenuates diverse prosurvival signaling cascades and decreases cell viability in human breast cancer cells.
    Gray GK; McFarland BC; Rowse AL; Gibson SA; Benveniste EN
    Oncotarget; 2014 Aug; 5(15):6484-96. PubMed ID: 25153725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein Kinase CK2 Regulates B Cell Development and Differentiation.
    Wei H; Yang W; Hong H; Yan Z; Qin H; Benveniste EN
    J Immunol; 2021 Aug; 207(3):799-808. PubMed ID: 34301844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic administration of antisense oligonucleotides simultaneously targeting CK2α and α' subunits reduces orthotopic xenograft prostate tumors in mice.
    Trembley JH; Unger GM; Tobolt DK; Korman VL; Wang G; Ahmad KA; Slaton JW; Kren BT; Ahmed K
    Mol Cell Biochem; 2011 Oct; 356(1-2):21-35. PubMed ID: 21761204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein Kinase CK2 Controls the Fate between Th17 Cell and Regulatory T Cell Differentiation.
    Gibson SA; Yang W; Yan Z; Liu Y; Rowse AL; Weinmann AS; Qin H; Benveniste EN
    J Immunol; 2017 Jun; 198(11):4244-4254. PubMed ID: 28468969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein kinase CK2 is important for the function of glioblastoma brain tumor initiating cells.
    Rowse AL; Gibson SA; Meares GP; Rajbhandari R; Nozell SE; Dees KJ; Hjelmeland AB; McFarland BC; Benveniste EN
    J Neurooncol; 2017 Apr; 132(2):219-229. PubMed ID: 28181105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
    Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F
    Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
    Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C
    BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CK2 kinase activity but not its binding to CK2 promoter regions is implicated in the regulation of CK2α and CK2β gene expressions.
    Lupp S; Gumhold C; Ampofo E; Montenarh M; Rother K
    Mol Cell Biochem; 2013 Dec; 384(1-2):71-82. PubMed ID: 23963994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
    Siddiqui-Jain A; Drygin D; Streiner N; Chua P; Pierre F; O'Brien SE; Bliesath J; Omori M; Huser N; Ho C; Proffitt C; Schwaebe MK; Ryckman DM; Rice WG; Anderes K
    Cancer Res; 2010 Dec; 70(24):10288-98. PubMed ID: 21159648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Growth, Anti-Angiogenic, and Pro-Apoptotic Effects by CX-4945, an Inhibitor of Casein Kinase 2, on HuCCT-1 Human Cholangiocarcinoma Cells via Control of Caspase-9/3, DR-4, STAT-3/STAT-5, Mcl-1, eIF-2α, and HIF-1α.
    Wang S; Yadav AK; Han JY; Ahn KS; Jang BC
    Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35683032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo.
    Hao Y; Chapuy B; Monti S; Sun HH; Rodig SJ; Shipp MA
    Clin Cancer Res; 2014 May; 20(10):2674-83. PubMed ID: 24610827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-adipogenic and Pro-lipolytic Effects on 3T3-L1 Preadipocytes by CX-4945, an Inhibitor of Casein Kinase 2.
    Yadav AK; Jang BC
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules.
    Brown MS; Diallo OT; Hu M; Ehsanian R; Yang X; Arun P; Lu H; Korman V; Unger G; Ahmed K; Van Waes C; Chen Z
    Clin Cancer Res; 2010 Apr; 16(8):2295-307. PubMed ID: 20371694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ROCK2-Specific Inhibitor KD025 Suppresses Adipocyte Differentiation by Inhibiting Casein Kinase 2.
    Tran NNQ; Chun KH
    Molecules; 2021 Aug; 26(16):. PubMed ID: 34443331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting CK2-driven non-oncogene addiction in B-cell tumors.
    Mandato E; Manni S; Zaffino F; Semenzato G; Piazza F
    Oncogene; 2016 Nov; 35(47):6045-6052. PubMed ID: 27041560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.